Immunovant to Host Virtual R&D Day on March 30, 2022
Retrieved on:
Monday, March 28, 2022
Graves' ophthalmopathy, Company, Medicine, Pritzker School of Medicine, FC, Private Securities Litigation Reform Act, Degenerative disease, Myasthenia gravis, Chicago (franchise), Royal College of Pathologists, NIHR, Malignancy, Blood transfusion, SEC, Royal Cornwall Hospitals NHS Trust, U.S. Securities and Exchange Commission, Security (finance), MD, Immunoglobulin G, Technology, Safety, Atorvastatin, Inflammation, Nasdaq, COVID-19, GLOBE, Professor, Annual report, University, Patient, Disease, Bachelor of Science, Antibody, Pharmaceutical industry, Neonatal Fc receptor
To attend the event, please register at: Immunovant R&D Day Registration .
Key Points:
- To attend the event, please register at: Immunovant R&D Day Registration .
- A replay of the event will be available on the Immunovant website following its conclusion.
- All forward-looking statements are based on estimates and assumptions by Immunovants management that, although Immunovant believes to be reasonable, are inherently uncertain.
- Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.